Alligator Bioscience Receives FDA Orphan Drug Designation for Mitazalimab in Pancreatic Cancer
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted O ...
Alligator Bioscience and Orion Corporation announce exercise of development option under their 2021 Immuno-oncology Research Collaboration and License Agreement
Orion selects lead antibodies from the first discovery program Collaboration aims to discover and develop new bispecific antibody cancer the ...
Alligator intends to carry out a 91 percent secured rights issue of units of approximately SEK 199 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Announces Positive Interim Results from Mitazalimab OPTIMIZE-1 Phase 2 Trial in Pancreatic Cancer Exceeding 50% Objective Response Rate
52% Objective Response Rate in pre-planned interim efficacy analysis of mitazalimab combined with mFOLFIRINOX in 1st line metastatic pancrea ...
Alligator Bioscience and Orion Corporation announce the initiation of the second program of their Immuno-oncology Research Collaboration and License Agreement
The second project aims to develop a bispecific antibody with potential applications in solid tumors Alligator and Orion each to provide val ...
Alligator announces preliminary outcome of rights issue
rights issue of shares (the “Rights Issue”) ended on 26 November 2021. The preliminary outcome shows that the Rights Issue has been oversubs ...
Alligator carries out a 100 percent secured rights issue of approximately SEK 257 million
The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has today, subject to approval by th ...
Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline
Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...
Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
Alligator Bioscience (Nasdaq Stockholm: ATORX) announced today that the company has entered into a research collaboration and license agreem ...